Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET ... - Markets Insider

Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET ... Markets Insider RET rearrangements and activating mutations are associated with several types of cancer, including non-small cell lung cancer, colorectal cancer and thyroid cancer.1,2,3. Under the terms of the agreement, Daiichi Sankyo grants Boston Pharmaceuticals ... and more »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vDgRg1
via IFTTT